Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels. (c) 2014 Elsevier Masson SAS. All rights reserved.
[EN] LIGANDS OF INSULIN DEGRADING ENZYME AND THEIR USES<br/>[FR] LIGANDS DE L'ENZYME DÉGRADANT L'INSULINE ET LEURS UTILISATIONS
申请人:UNIV LILLE II DROIT & SANTE
公开号:WO2011107948A2
公开(公告)日:2011-09-09
The invention relates to ligands of insulin degrading enzyme and to their uses. The ligands of the invention are non peptidic and bind specifically to the exosite of insulin degrading enzyme. They are useful, in particular a use in the pharmaceutical field.
Ligands of insulin degrading enzyme and their uses
申请人:Université de Lille 2 Droit et Santé
公开号:EP2371421A1
公开(公告)日:2011-10-05
The invention relates to ligands of insulin degrading enzyme and to their uses.
The ligands of the invention are non peptidic and bind specifically to the exosite of insulin degrading enzyme.
They are useful, in particular a use in the pharmaceutical field.